CTXR

+ Watchlist + Portfolio

Citius Pharmaceuticals, Inc.

Regulated industry Physical products Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.54
52-Week Range: $0.47 – $2.19
Market Cap: $14.59M
P/E (TTM): —
EPS (TTM): -1.75
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.22
PEG Ratio: —
Return on Equity: -81.09%
Return on Assets: -26.57%
Gross Margin: 77.34%
Operating Margin: -670.23%
Profit Margin: 0.00%
Current Ratio: 0.84
Debt/Equity: 0.09
Total Debt: $7.18M
Free Cash Flow: $-36.80M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $14.06M

CTXR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$17.66M	$14.82M	$11.91M	$9.16M
Selling, General & Admin	$15.66M	$21.91M	$30.09M	$29.37M
Operating Expenses	$33.32M	$36.73M	$42.00M	$38.53M
Operating Income	-$33.32M	-$36.73M	-$42.00M	-$38.53M
EBITDA	-$33.14M	-$36.54M	-$41.79M	-$38.20M
Pretax Income	-$33.06M	-$31.97M	-$38.85M	-$38.68M
Income Tax	$576.00K	$576.00K	$576.00K	$1.06M
Net Income	-$33.64M	-$32.54M	-$39.14M	-$37.43M
Diluted EPS	-5.75	-5.57	-5.97	-3.38
Diluted Shares	5.84M	6.05M	6.73M	11.07M

CTXR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$41.71M	$26.48M	$3.25M	$4.25M
Inventory	—	$0.00	$8.27M	$22.29M
Current Assets	$44.56M	$34.37M	$14.22M	$27.93M
Total Assets	$114.00M	$103.61M	$116.65M	$130.94M
Current Liabilities	$4.53M	$5.78M	$35.81M	$44.91M
Total Debt	$678.23K	$481.25K	$262.87K	$1.81M
Total Liabilities	$10.57M	$12.18M	$42.55M	$53.41M
Retained Earnings	-$129.69M	-$162.23M	-$201.37M	-$238.80M
Shareholders' Equity	$102.83M	$90.83M	$70.08M	$67.55M
Working Capital	$40.03M	$28.59M	-$21.59M	-$16.98M

CTXR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$28.36M	-$29.06M	-$28.20M	-$26.55M
Free Cash Flow	-$28.36M	-$29.06M	-$28.20M	-$26.55M
Depreciation & Amortisation	$179.68K	$194.32K	$209.61K	$214.25K
Stock-Based Compensation	$3.91M	$6.62M	$11.84M	$10.84M
Investing Cash Flow	$0.00	$0.00	-$5.00M	-$5.75M
Financing Cash Flow	$0.00	$13.83M	$9.97M	$33.30M
Net Change in Cash	-$28.36M	-$15.23M	-$23.23M	$1.00M

CTXR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$3.94M	$1.67M	$1.49M
Cost of Revenue	$0.00	$0.00	—	$789.21K	$328.88K	$491.84K
Gross Profit	$0.00	$0.00	—	$3.15M	$1.34M	$1.00M
Research & Development	$3.77M	$1.62M	$1.64M	$1.60M	$1.63M	$1.05M
Selling, General & Admin	$7.49M	$7.17M	$6.80M	$10.00M	$30.18M	$9.96M
Operating Expenses	$11.26M	$8.79M	$8.44M	$11.60M	$31.81M	$11.01M
Operating Income	-$11.26M	-$8.79M	-$8.44M	-$8.45M	-$30.47M	-$10.01M
EBITDA	-$11.19M	-$8.73M	-$8.32M	-$8.97M	-$28.27M	-$11.75M
Pretax Income	-$11.25M	-$8.94M	-$8.48M	-$9.13M	-$28.34M	-$12.03M
Income Tax	$264.24K	$264.24K	$264.24K	$264.24K	-$231.21K	-$107.35K
Net Income	-$10.92M	-$8.79M	-$7.96M	-$8.22M	-$21.23M	-$8.86M
Diluted EPS	-1.27	-0.80	—	-0.38	-0.95	-0.34
Diluted Shares	8.58M	11.01M	—	21.50M	22.38M	26.17M

CTXR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$26.41K	$6.09M	$4.25M	$7.72M	$4.59M	$17.01M
Receivables	—	—	—	$4.05M	$1.08M	$686.24K
Inventory	$15.34M	$17.21M	$22.29M	$22.64M	$22.66M	$22.63M
Current Assets	$18.37M	$24.61M	$27.93M	$37.95M	$31.69M	$43.33M
Total Assets	$121.48M	$127.68M	$130.94M	$140.39M	$132.54M	$142.26M
Current Liabilities	$49.88M	$51.84M	$44.91M	$38.21M	$55.02M	$51.65M
Long-Term Debt	—	—	—	—	—	$6.41M
Total Debt	$931.79K	$1.88M	$1.81M	$1.83M	$808.16K	$7.18M
Total Liabilities	$57.91M	$60.12M	$53.41M	$46.92M	$63.46M	$66.35M
Retained Earnings	-$222.05M	-$230.84M	-$238.80M	-$247.02M	-$268.26M	-$277.12M
Shareholders' Equity	$60.66M	$65.06M	$67.55M	$79.96M	$61.54M	$66.61M
Working Capital	-$31.50M	-$27.23M	-$16.98M	-$261.99K	-$23.33M	-$8.32M

CTXR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$4.54M	-$5.41M	-$11.88M	-$13.01M	-$1.30M	-$8.68M
Free Cash Flow	-$4.54M	-$5.41M	-$11.88M	-$13.01M	-$1.30M	-$8.68M
Depreciation & Amortisation	$56.01K	$41.37K	$62.04K	-$16.48K	$40.66K	$41.48K
Stock-Based Compensation	$2.70M	$2.72M	$2.89M	$4.28M	$3.79M	$3.81M
Investing Cash Flow	$0.00	$0.00	—	-$4.40M	-$600.00K	-$2.00M
Financing Cash Flow	$3.47M	$11.47M	$15.79M	$20.88M	-$1.23M	$23.09M
Net Change in Cash	-$1.07M	$6.06M	-$1.84M	$3.47M	-$3.13M	$12.42M

Market Snapshot

About

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to developing and commercializing critical care products. Based in Cranford, New Jersey, the company focuses on anti-infectives, cancer care, and prescription products. Citius Pharmaceuticals' pipeline includes treatments for acute bacterial skin infections, hemorrhagic cystitis, and other conditions requiring urgent medical intervention. The company pursues both novel formulations and improved delivery mechanisms for existing therapeutic compounds.